Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2019
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - January 20, 2019

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/20/19 - Procurement Of Services For The Maintenance And Repair Of Medical Equipment Installed In The Department Of Regenerative Medicine And Cell Therapy At The Address: Minsk, Ul. P. Brovka, 15 A-2 [TendersInfo (India)]
Request for quotations: procurement of services for the maintenance and repair of medical equipment installed in the department of regenerative medicine and cell therapy at the address: minsk, ul. p. brovka, 15 a-2. 2. execution of technical maintenance and current repair of the table of general surgical ok-gamma mobile, installed in the department
1/20/19 - Purchase Of Veterinary Drugs, Disinfectants, Veterinary Products [TendersInfo (India)]
Request for quotations: purchase of veterinary drugs, disinfectants, veterinary products. Date and time of the end of acceptance of offers: 01.02. 2019 00:00 Major organization: OPEN JOINT STOCK COMPANY VICTORY Address: Republic Of Belarus, Brest Region, Ag. Vulka Obrovskaya, 225259, 225259, Brest Region, Ivatsevichi District, Ag.
1/19/19 - 10 bots Vaccines: HS Scepticemia Vaccines 100ml and other items for Integrated Community Food Production Program (ICFP) [TenderNews.com - Tenders (India)]
10 bots Vaccines: HS Scepticemia Vaccines 100 ml and other items for Integrated Community Food Production Program more info: Location: Negros Oriental BidDate: 1/ 24/ 2019 Tender Country: Philippines Tender Type: Tenders Tendering Authority: CITY OF DUMAGUETE, NEGROS ORIENTAL Tendering Authority Address: Christie Magdalene J Pedroza Clerk City Hall
1/19/19 - AIVITA gets IND nod for Phase 1B melanoma trial [Syrian Arab News Agency]
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 1 B clinical trial investigating the Company`s ROOT OF CANCER technology in patients with metastatic melanoma. AIVITA`s ROOT OF CANCER...
1/19/19 - Algerian, German corporations ink 22.86-mln-USD deal for native manufacturing of medicines [Sun, The (Nigeria)]
Abdi Ibrahim, a Turkish-Algerian joint venture pharmaceutical company, said on Tuesday that it signed a 20- million-euro agreement with German pharmaceutical company Boehringer Ingelheim for local production of blood pressure and diabetes medicines. The JARDIANCE medication will be produced from the second half of 2019, said Bachir Batel, director.
1/19/19 - Alphabet's health division gets clearance for on-demand ECG feature in smartwatch [Asian News International]
California, January 19: After Apple, Google' s parent company Alphabet is working its way towards bringing health at the center of its products. Now, the company's health division Verily has reportedly received FDA 510 clearance for its Study smartwatch for an on-demand ECG feature. The feature is increasingly becoming a standard for a lot of manuf
1/19/19 - Antibody Drug Conjugates Market Set to Garner Staggering Revenues by 2020
Albany, NY 01/19/2019 The global Antibody Drug Conjugates Market are very effective biopharmaceuticals developed as the targeted therapeutic helpful in the treatment of Cancer. Antibody drugs conjugates are further designed to eradicate the cancer cells without harming the normal cells. Of these, Adcertis drug segment dominate this market due
1/19/19 - Automated Microbiology Testing Market: North America is the most dominating region for this market
"Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on the gamut of sectors across the globe" The aging workforce in laboratory tests, the growing demand for high quality laboratory services and the growing need for fast results will lead to the expansion of the global market fo
1/19/19 - Bee Pollen Supplements Market Soaring Demand Assures Motivated Revenue Share During 2018 to 2026: Fact.MR has announced the addition of the Bee Pollen Supplements Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 201
Rockville, MD 01/19/2019 Bee pollen is a mixture of pollens picked by bees, bee saliva, and some nectar. Bee pollen Supplements have been popular for its high nutrient content and medicinal properties. German Federal Board of Health has recognized bee pollen supplements as medicine, owing to its medicinal benefits.
1/19/19 - Big Pharma Poised for Disruption in 2019 While Mid-Tier Companies Double Down on Innovation
Jones Lang LaSalle issued the following news release:. Small and mid-tier companies are responsible for 63 percent of new products brought to market since 2013, according to HBM Partners, making 2019 the year for Big Pharma to add more innovation to its business model. "Without productive, efficient R&D processes that deliver strong revenues to dr
1/19/19 - Biosimilar Drugs Market - a Cost-Saving Option to Expensive Biologics: Overview of How Much Have CMOs Benefited from Biosimilars
Albany, NY 01/19/2019 Biosimilars are drugs that are highly similar but not identical to branded innovator biologics: large molecule, immunogenic drugs produced from living cells. Innovator biologics are the first to be approved, and when their patent protection expires, biosimilars may be approved, in a similar way to small molecule branded
1/19/19 - Business Digest
Waltham-based AMAG Pharmaceuticals said it has completed a previously announced acquisition of Perosphere Pharmaceuticals, a private biopharmaceutical company. Through this acquisition, AMAG adds ciraparantag to its development portfolio. Ciraparantag has been granted fast track review designation by the U.S. Food and Drug Administration and has...
1/19/19 - Cancer Comorbidities Adversely Associated With Clinical Trial Participation [T-break Tech (Middle East)]
The American Society of Clinical Oncology, Friends of Cancer Research, and the US Food and Drug Administration recently recommended modernizing criteria related to comorbidities routinely used to exclude patients from cancer clinical trials. The goal was to design clinical trial eligibility such that trial results better reflect real-world cancer..
1/19/19 - Caplin Steriles gets INR 218 crore investment from Eight Roads Ventures and F-Prime Capital [Daily Independent (Nigeria)]
Caplin Point Laboratories Limited, one of the fastest growing pharmaceutical companies in India, today announced an investment in its injectables subsidiary, Caplin Steriles, by Eight Roads Ventures, the proprietary investment arm of FIL, Fidelity International Limited and its US-based sister fund, FPrime Capital. Caplin Point was founded in 1990 b
1/19/19 - Cellular Biomedicine Group`s AlloJoin Therapy for Knee Osteoarthritis (KOA) Becomes the First Stem Cell Drug Application Approved in China for Phase II Clinical Trials [Sport360]
Cellular Biomedicine Group, Inc., a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that its off-the-shelf allogeneic adipose-derived mesenchymal progenitor cell AlloJoin therapy for Knee Osteoarthritis has been approved as the first stem cell KOA...
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement According To 130a Abs. 8 Sgb V On The Active Ingredient Clonazepam, Atc N03ae01, For The Period 1.2.2019-31.1.2021 [TendersInfo (India)]
Dak-gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. irrespective of this, it automatically ends with the entry into force of the exclusive contract for clonazepam, atc n03ae01, as a result of a forma
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement According To 130a Abs. 8 Sgb V On The Active Ingredient Everolimus, Atc L01xe10, For The Period 1.2.2019 - 31.1.2021 [TendersInfo (India)]
Dak-gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. irrespective of this, it automatically ends with the entry into force of the exclusive contract for everolimus, atc l01xe10, as a result of a forma
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement According To 130a Abs. 8 Sgb V On The Active Ingredient Formoterol (exclusively Dos), Atc R03ac13, For The Period 1.2.2019 - 31.12.2020 [TendersInfo (India)]
Dak-gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus non-discriminatory access of all pharmaceutical companies, and automatically ends with the entry into force of the formoterol exclusive agreement, atc r03ac13, following a formal award procedure in accordance w
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement According To 130a Abs. 8 Sgb V On The Active Substance Aripiprazole, Atc N05ax12 (only Dafo For Intramuscular Injection), For The Period 1.2.2019 - 31.1.2021 [TendersInfo (India)]
The dak-g assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. irrespective of this, it automatically ends with the entry into force of the exclusive agreement on aripiprazole as a result of a formal award procedure
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement According To 130a Abs. 8 Sgb V On The Active Substance Calcipotriol And Betamethasone, Atc D05ax22, For The Period 1.2.2019 - 31.1.2021 [TendersInfo (India)]
Dak-gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. irrespective of this, it automatically ends with the entry into force of the exclusive agreement on calcipotriol and betamethasone, atc d05ax22, as
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement According To 130a Abs. 8 Sgb V On The Active Substance Colecalciferol (oily Drops), Atc A11cc05, For The Period 1.2.2019 - 31.12.2020 [TendersInfo (India)]
Dak-gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies and automatically ends with the entry into force of the exclusive contract for colecalciferol, atc a11cc05, following a formal procurement procedure
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement According To 130a Abs. 8 Sgb V On The Active Substance Lipegfilgrastim (atc L03aa14), For The Period 1.2.2019 - 31.1.2021 [TendersInfo (India)]
The dak-g assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. irrespective of this, it automatically ends with the entry into force of the exclusive contract for lipegfilgrastim as a result of a formal award proced
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement Pursuant To 130a (8) Sgb V On Medicines Containing The Active Substance Darunavir (atc Code: J05ae10) [TendersInfo (India)]
For the active substance darunavir, the aok- die gesundheitskasse fr niedersachsen offers rebate contracts to all interested pharmaceutical companies for the period up to the entry into force of exclusive contracts following a formal award procedure in accordance with the regulations of the 4th part of the gwb on. the contracts are concluded as par
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement Pursuant To 130a (8) Sgb V On The Active Substance Gefitinib (atc L01xe02), For The Period 1.2.2019 - 31.1.2021 [TendersInfo (India)]
The dak-g assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. irrespective of this, it automatically ends with the entry into force of the exclusive agreement on gefitinib, following a formal award procedure in acc
1/19/19 - Conclusion Of A Non-exclusive Discount Agreement Pursuant To 130a (8) Sgb V On The Active Substance Ritonavir, Atc J05ae03, For The Period 1.2.2019 - 31.1.2021 [TendersInfo (India)]
Dak-gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory access of all pharmaceutical companies. irrespective of this, it automatically ends with the entry into force of the exclusive agreement on ritonavir, atc j05ae03, as a result of a formal
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415